The origin of all biological movements, including walking, swimming, or flying, can be traced back to cellular movements; however, little is known about how cell motility arose in evolution.
Jurata Thin Film, a startup focused on stabilizing vaccines at ambient temperature has raised initial investment funds totaling $4.87 million to develop the technology.
When neurons are damaged by degenerative disease or injury, they have little, if any, ability to heal on their own. Restoring neural networks and their normal function is therefore a significant challenge in the field of tissue engineering. Prof. Orit Shefi and doctoral student Reut Plen from the Kofkin Faculty of Engineering at Bar-Ilan University have developed a novel technique to overcome this challenge using nanotechnology and magnetic manipulations, one of the most innovative approaches to creating neural networks.
Molecular biologist Yu Xin (Will) Wang, Ph.D., has joined Sanford Burnham Prebys as an assistant professor in the Development, Aging, and Regeneration Program to uncover the ways muscle, nerve and immune cells work together to overcome disease.
BACKGROUNDCartilage tissue engineering is a promising strategy for treating cartilage damage. Matrix formation by adipose-derived stem cells (ADSCs), which are one type of seed cell used for cartilage tissue engineering, decreases in the late s
Corneal stem/progenitor cells are typical adult stem/progenitor cells. The human cornea covers the front of the eyeball, which protects the eye from the outside environment while allowing vision. The location and function demand the cornea to m
Nyra Medical, Inc., a medical device company that is developing a novel transcatheter mitral valve repair technology, today announced the closing of a $20 million Series A financing.
The Euglena International Network (EIN) (https://euglenanetwork.org/), founded in 2020, is a global consortium of hundreds of scientists around the world with the collective goal of supporting euglenoid science through collaborative and integrative omics between academics and industry.
UC San Diego Alpha Stem Cell Clinic awarded $8M to expand clinical trials of novel stem cell therapies. The CIRM award will advance partnerships between academic and industry experts in San Diego to expedite clinical trials for patients with difficult-to-treat diseases.
The transport protein named STARD3 is thought to be responsible for the accumulation of carotenoids in the human retina. It is carotenoids that work in the so-called “yellow spot” (macula lutea) of the retina, protecting it from oxidative stress and age-related degeneration.
Science misinformation about genetically modified crops and foods had a potential global readership of over a quarter of a billion people, according to a new study published by the Alliance for Science, which combats anti-science misinformation on topics like climate, vaccines and GMOs.
The goal of the project is to create a membrane-based downstream purification platform for large-scale continuous biomanufacturing of viral vectors and virus-like particles (VLPs).
Empa researchers are developing a medical chip in collaboration with the ETH Zurich and the Cantonal Hospital of St.Gallen that will allow statements to be made about the effect of substances on babies in the womb. The Zurich-based ProCare Foundation is funding the project, which was recently launched.
RareCyte Inc., ("RareCyte" or "The Company") a leading provider of Precision Biology products and services has been selected by Wellcome Leap to participate in the $50M In Utero program to create the scalable capacity to measure, model and predict gestational development, to achieve the goal of reducing global stillbirth rates by half.
Bringing together concepts from electrical engineering and bioengineering tools, Technion and MIT scientists collaborated to produce cells engineered to compute sophisticated functions – “biocomputers” of sorts.
Multilab research shows that biofuel combined with advanced engine design can reduce greenhouse gas emissions while improving fuel efficiency or reducing tailpipe emissions.
For the first time, scientists have used CRISPR technology to insert genes that allow immune cells to focus their attack on cancer cells, potentially leaving normal cells unharmed and increasing the effectiveness of immunotherapy.
A new study being presented at this year’s ACAAI Annual Scientific Meeting shows a treatment using the CRISPR genome editing technology succeeded in alleviating swelling and reducing the frequency of attacks.
Un nuevo estudio que se presenta en la Reunión Científica Anual del ACAAI de este año muestra que un tratamiento que usa una tecnología de edición genética de repeticiones palindrómicas cortas, agrupadas y regularmente interespaciadas logró aliviar la inflamación y reducir la frecuencia de los ataques.
The costliness of drug development and the limitations of studying physiological processes in the lab are two separate scientific issues that may share the same solution.
Heather Wojcik, Harold N Lovvorn, Melinda Hollingshead, Janene Pierce, Howard Stotler, Andrew J Murphy, Suzanne Borgel, Hannah M Phelps, Hernan Correa, Alan O Perantoni
Andrej Thurzo, Paulína Gálfiová, Zuzana Varchulová Nováková, Štefan Polák, Ivan Varga, Martin Strunga, Renáta Urban, Jana Surovková, Ľuboš Leško, Zora Hajdúchová, Jozef Feranc, Marian Janek, Ľuboš Danišovič
When starved of glucose, yeast kills its own clones and other surrounding microorganisms to survive in a newly discovered phenomenon named latecomer killing.
Sophie Girardin, Stephan Johannes Ihle, Arianna Menghini, Magdalena Krubner, Leonardo Tognola, Jens Duru, Tobias Ruff, Isabelle Fruh, Matthias Muller, János Vörös